Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with cancer more than a decade ago - but he still lives with the disease.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

This article was reviewed by Knox Beasley. Key Takeaways: 1mg oral finasteride effectively treats hair loss and is the ...

John Tesh reveals how wife Connie Sellecca saved his life during prostate cancer battle. The former TV host credits faith and ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

Cast urge men to get checked for prostate cancer.

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

He was only given 18 months to live.

Heaven’s Beverley Mitchell reflected on a life-changing experience when doctors found the “biggest precancerous polyp” on her ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

The Reverend Richard Andrew, president of the Methodist Conference and chair of the Darlington Methodist District, is urging ...

John Tesh has outlived his prognosis by nearly eight years after doctors told him in 2015 he had only 18 months to live, Page Six reports. The former “Entertainment Tonight” co-host told reporters in ...